Update on cerebrotendinous xanthomatosis.
DeBarber AE, Duell PB.
Curr Opin Lipidol. 2021 Apr 1;32(2):123-131. doi: 10.1097/MOL.0000000000000740.
Cerebrotendinous xanthomatosis.
Björkhem I.
Curr Opin Lipidol. 2013 Aug;24(4):283-7. doi: 10.1097/MOL.0b013e328362df13.
Case report: Cerebrotendinous xanthomatosis treatment follow-up.
Ejsmont-Sowała K, Książek T, Maciorowska-Rosłan K, Rosłan J, Czarnowska A, Jakubiuk-Tomaszuk A, Tarasiuk J, Kapica-Topczewska K, Kułakowska A.
Front Neurol. 2024 Jun 17;15:1409138. doi: 10.3389/fneur.2024.1409138. eCollection 2024.
Movement disorders in cerebrotendinous xanthomatosis.
Stelten BML, van de Warrenburg BPC, Wevers RA, Verrips A.
Parkinsonism Relat Disord. 2019 Jan;58:12-16. doi: 10.1016/j.parkreldis.2018.07.006. Epub 2018 Jul 19.
Cerebrotendinous xanthomatosis revisited.
Baghbanian SM, Mahdavi Amiri MR, Majidi H.
Pract Neurol. 2021 Jun;21(3):243-245. doi: 10.1136/practneurol-2020-002895. Epub 2021 Apr 14.
Cerebrotendinous xanthomatosis.
Vadapalli S.
Indian J Orthop. 2013 Mar;47(2):200-3. doi: 10.4103/0019-5413.108918.
Cerebrotendinous xanthomatosis, sitosterolemia, Smith-Lemli-Opitz syndrome and the seminal contributions of Gerald Salen, MD (1935-2020).
Schaefer EJ, Tint GS, Duell PB, Steiner RD.
J Clin Lipidol. 2021 Jul-Aug;15(4):540-544. doi: 10.1016/j.jacl.2021.05.004. Epub 2021 May 28.
Cerebrotendinous xanthomatosis: The rare "treatable" disease you never consider.
Raymond GV, Schiffmann R.
Neurology. 2019 Jan 8;92(2):61-62. doi: 10.1212/WNL.0000000000006721. Epub 2018 Dec 7.
Cerebrotendinous xanthomatosis without neurological involvement.
Stelten BML, Raal FJ, Marais AD, Riksen NP, Roeters van Lennep JE, Duell PB, van der Graaf M, Kluijtmans LAJ, Wevers RA, Verrips A.
J Intern Med. 2021 Nov;290(5):1039-1047. doi: 10.1111/joim.13277. Epub 2021 Apr 8.
Cerebrotendinous xanthomatosis: A case report.
Xiao Z, Li L, Liao W, Li Z.
Asian J Surg. 2022 Feb;45(2):786-787. doi: 10.1016/j.asjsur.2021.11.063. Epub 2022 Jan 3.
